How Smoking Causes COPD: Examination of Immune System Changes

The recruitment status of this study is unknown because the information has not been verified recently.

Verified July 2011 by St. Joseph's Healthcare Hamilton.
Recruitment status was Recruiting

Sponsor:

Information provided by:

St. Joseph's Healthcare Hamilton

ClinicalTrials.gov Identifier:

NCT00186719

First received: September 13, 2005

Last updated: July 25, 2011

Last verified: July 2011

History of Changes

Purpose

A breathing condition known as "chronic obstructive pulmonary disease" (COPD) caused by cigarette smoking is a major health problem. The way by which smoking leads to lung disease is uncertain. Recent research done in animals provides a description of specific changes (that is a reduction) in these immune cell types as a result of cigarette smoke exposure. The study you have been asked to participate in is a pilot study to see if similar changes occur in humans who smoke. The purpose of this study is to evaluate this new method of testing blood in 3 groups of 10 people: normal non-smoking subjects, subjects who smoke with no history of lung disease and subjects who smoke and have smoking related COPD.

Condition
Chronic Obstructive Pulmonary Disease


Study Type:	Observational
Study Design:	Observational Model: Cohort Time Perspective: Prospective
Official Title:	How Smoking Causes COPD: Examination of Immune System Changes

Resource links provided by NLM:

MedlinePlus related topics: COPD Lung Diseases Smoking

U.S. FDA Resources

Further study details as provided by St. Joseph's Healthcare Hamilton:


Estimated Enrollment:	100
Study Start Date:	May 2005
Estimated Study Completion Date:	April 2012

Detailed Description:

The mechanism by which smoking leads to damage to lung tissue in susceptible hosts, is uncertain. Recently there has been description of specific changes (that is reduction) in the number and activity of certain key immune cell types - dendritic cells- as a result of cigarette smoke exposure. This work was done in animal models and we would like to develop methods that will allow us to examine if similar changes occur in humans who smoke. Reduced number and activity of dendritic cells would be expected to lead to increased incidence of infection - a common problem in patients with COPD.

Since dendritic cells come to the lung from the bloodstream, and one can detect them in the circulation, we will look at the dendritic cells that are present in the peripheral blood.

Eligibility


Ages Eligible for Study:	40 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes
Sampling Method:	Probability Sample

Study Population

smokers and non-smokers

Criteria

Inclusion Criteria:

Age > 40 years
Healthy Subjects - Non smokers
FEV1/FVC > 70% predicted
Current Smokers - > 10 pack year smoking history
FEV1/FVC > 70% predicted
Current Smokers with COPD - > 10 pack year smoking history
FEV1/FVC < 70% predicted
Able to give informed consent

Exclusion Criteria:

Healthy Subjects - Reside with smokers
History of lung disease
Current Smokers - History of lung disease

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00186719

Contacts


Contact: Susan E Carruthers, MLT	905-522-1155 ext 2208	scarruth@stjosham.on.ca
Contact: Sarah E Goodwin, BA RRT CCRC	905-522-1155 ext 6130	sgoodwin@stjosham.on.ca

Locations


Canada, Ontario
St Joseph's Healthcare	Recruiting
Hamilton, Ontario, Canada, L8N 4A6
Contact: Gerard Cox, MB FRCPC FRCPI 905-522-1155 ext 5039 coxp@mcmaster.ca
Contact: Martin Stampfli, PhD 905-525-9140 ext 22473 stampfli@mcmaster.ca
Principal Investigator: Gerard Cox, MB FRCPC FRCPI
Sub-Investigator: Martin Stampfli, PhD

Sponsors and Collaborators

St. Joseph's Healthcare Hamilton

Investigators


Principal Investigator:	Gerard Cox, MB FRCPC FRCPI	McMaster University

More Information

No publications provided


Responsible Party:	Dr. Gerard Cox, St. Joseph's Healthcare Hamilton
ClinicalTrials.gov Identifier:	NCT00186719 History of Changes
Other Study ID Numbers:	02-2182
Study First Received:	September 13, 2005
Last Updated:	July 25, 2011
Health Authority:	Canada: Health Canada

Keywords provided by St. Joseph's Healthcare Hamilton:


Chronic Obstructive Pulmonary Disease Smoking Related Disease Immune System Changes

Additional relevant MeSH terms:


Lung Diseases Lung Diseases, Obstructive Pulmonary Disease, Chronic Obstructive Respiratory Tract Diseases

ClinicalTrials.gov processed this record on February 27, 2015

To Top